Clinical trial
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent…
NCT00104780 · Epimmune, Industry · Unknown status
Key facts
| NCT number | NCT00104780 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer |
| Official title | A Phase II, Open Label, Multi-center Study of EP2101 Therapeutic Vaccine in Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Epimmune, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological |
| Interventions | EP-2101, incomplete Freund's adjuvant |
| Start date | Dec 1, 2004 |
| First posted | Mar 4, 2005 |
| Last update posted | Nov 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: